AEZS-134

N/A

Report date: 2025/06/11 11:08:12

NME

Base Information

Drug NameAEZS-134

Drug Alias Namepyrido[2,3-b]pyrazine compounds (AEterna Zentaris)ERK1/2 inhibitor (Aeterna)AEZS-131AEZS-140AEZS-134

ClassificationSmall molecules

Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsAnticancer protein kinase inhibitorsExtracellular-signal-regulated kinase 2 inhibitors +[4]

TargetsExtracellular-signal-regulated kinase1Extracellular-signal-regulated kinase 2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCOSCIENS Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesCOSCIENS Biopharma Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A